True Innovation In Women’s Health Hindered Because Conditions Are Not Fatal
Drug developers and financiers discuss the biggest challenges delaying novel R&D in diseases effecting only women and how poor awareness of the debilitating symptoms that come with some conditions has led to a lack of emphasis on innovative research.
You may also be interested in...
The firms have inked a collaboration which aims to explore individual differences in women’s responses to IVF treatment, improve success rates and reduce side effects such as ovarian hyper-stimulation syndrome.
In addition to endometriosis, Orilissa (elagolix), developed by Neurocrine and licensed to Abbvie, is in Phase III for treating heavy bleeding associated with uterine fibroids.
Faster relief of debilitating menopausal symptoms in early-stage clinical trial results suggest a potential new class of products being evaluated by UK biotech KaNDy Therapeutics may be useful against the condition.